Overview

Study of Combination Therapy With SYR-322

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy and safety of SYR-322 (alogliptin) 25-mg, once daily (QD), in patients with diabetes when used in combination with insulin.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Alogliptin
Insulin
Insulin, Globin Zinc